Skip to main content

$0.043 0.002 (4.88%)

High

$0.05

Low

$0.04

Trades

61

Turnover

$61,445

Volume

1,415,719
30 June 2023 at 4:10pm
Register to track NOX and receive email alerts.
Subject
NOX Ann: Noxopharm Corporate Presentation

NOX Ann: Veyonda Abstract Published at ASCO Annual Meeting 2022

NOX Ann: March 2022 Quarterly Activities Report and Appendix 4C

NOX Ann: Orphan Drug Designation Granted to Noxopharm by US FDA

NOX Ann: First Patient Treated in CEP-2 Sarcoma Trial

NOX Ann: Appendix 4D and Half Year 2022 Financial Report

NOX Ann: Initial Director's Interest Notice - GM

NOX Ann: December 2021 Quarterly Activities Report and Appendix 4C

NOX Ann: Noxopharm Presents at H.C. Wainwright BioConnect Conference

NOX Ann: Noxopharm Receives A$5.865M R & D Tax Rebate

NOX Ann: Noxopharm Announces Leadership Transition

NOX Ann: Noxopharm DARRT-2 Cancer Trial Update

NOX Ann: Notification of cessation of securities - NOX

NOX Ann: Change of Director's Interest Notice - GK

NOX Ann: Noxopharm Annual General Meeting Results

NOX Ann: Licencing Deal Expands Noxopharm Drug Opportunities

NOX Ann: Noxopharm 2021 AGM Corporate Presentation

NOX Ann: Noxopharm 2021 AGM Chairmans Address

NOX Ann: Retraction of Grant Announcement

NOX Ann: Trading Halt

NOX Ann: Noxopharm Awarded A$8.8M Aust Govt Grant for Sarcoma Trial

NOX Ann: DARRT-2 Trial Commences in the U.S.

NOX Ann: Unlisted Options Expiring on 30 November 2021

NOX Ann: Veyonda and Opdivo IONIC Study First Patient Dosed

NOX Ann: Patent Granted for Veyonda and Low Dose Chemotherapy

NOX Ann: Jobkeeper s323DB Notice

NOX Ann: 2021 AGM Notice of Meeting and Proxy

NOX Ann: 2021 AGM Letter to Shareholders and Proxy

NOX Ann: September 2021 Quarterly Activities Report and Appendix 4C

NOX Ann: Cleansing Notice

NOX Ann: Application for quotation of securities - NOX

NOX Ann: Veyonda Achieves Important U.S. Patent Claims

NOX Ann: Noxopharm 2021 Annual Report

NOX Ann: Noxopharm Updated Corporate Presentation

NOX Ann: Change of Registered Office and Principal Place of Business

NOX Ann: Appendix 4E and Audited Financial Statements

NOX Ann: Appendix 4G and Corporate Governance Statement

NOX Ann: Cleansing Notice

NOX Ann: Application for quotation of securities - NOX

NOX Ann: Pre-clinical Data Supports a Role for Veyonda in COVID-19

NOX Ann: NOXCOVID Program to Expand After Positive Phase 1 Results

NOX Ann: Trading Halt

NOX Ann: Cleansing Notice

NOX Ann: Application for quotation of securities - NOX

NOX Ann: Additional Information on US NCI Collaboration

NOX Ann: NOX and US Govt Peak Cancer Agency Announce Collaboration

NOX Ann: Veyonda Survival Advantage in LuPSMA Therapy Confirmed

NOX Ann: June 2021 Quarterly Activities Report and Appendix 4C

NOX Ann: DARRT-2 Study Receives IND Approval from FDA

NOX Ann: Noxopharm Secures Key European Patent Allowance for Veyonda

Register to track NOX and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC
TLX